Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio announced a transformational oversubscribed $275 million private placement led by BVF, securing capital to fund its Phase 3 registrational program for EB613 and extending its cash runway into 2030. The company confirmed FDA alignment on a single 12-month Phase 3 study for EB613 in postmenopausal osteoporosis, with topline data anticipated in the second half of 2028, and reported positive data for its EB612 and EB618 candidates.
Key figures
- Revenue
- 0
- Deal Value Usd
- 275000000
- Runway
- into 2030
- Net loss
- 7312000
- Ga expenses
- 1362000
- Rd expenses
- 3201000
- Phase3 start
- late 2026
- Cash position
- 11309000
- Restricted cash
- 7122000
- Topline data expected
- second half of 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.